BioAge Labs, Inc.
$18.8
▼
-1.3%
2026-04-21 05:40:00
bioagelabs.com
NMS: BIOA
Explore BioAge Labs, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$820.58 M
Current Price
$18.8
52W High / Low
$24 / $3.63
Stock P/E
—
Book Value
$7.28
Dividend Yield
—
ROCE
-33.77%
ROE
-27.09%
Face Value
—
EPS
$-2.04
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
60
Beta
—
Debt / Equity
2.04
Current Ratio
14.24
Quick Ratio
14.24
Forward P/E
-5.83
Price / Sales
79.88
Enterprise Value
$442.97 M
EV / EBITDA
-4.79
EV / Revenue
49.25
Rating
Buy
Target Price
$53.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Perrigo Company plc | $12.04 | — | $1.66 B | 9.63% | 4.16% | -38.66% | $28.43 / $9.22 | $21.33 |
| 2. | China SXT Pharmaceuticals, Inc. | $2.06 | — | $1.97 M | — | -17.13% | -50.3% | $1,046.98 / $1.25 | $26.16 |
| 3. | United Therapeutics Corporation | $578.37 | 20.76 | $25.34 B | — | 20.73% | 19.71% | $607.89 / $272.12 | $162.6 |
| 4. | Gelteq Limited | $0.7 | — | $7.5 M | — | -31.25% | -42.99% | $4.11 / $0.64 | $1.09 |
| 5. | Dr. Reddy's Laboratories Limited | $12.97 | 17.86 | $11.1 B | 0.65% | 19.86% | 16.1% | $1,379.7 / $1,129 | $4.78 |
| 6. | Cardiol Therapeutics Inc. | $1.51 | — | $230.46 M | — | -162.05% | -1.59% | $2.17 / $1.23 | $0.08 |
| 7. | Phibro Animal Health Corporation | $56.51 | 24.91 | $2.29 B | 0.85% | 10.35% | 31.8% | $60.08 / $16.16 | $8.2 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.08 M | 2.05 M | 2.41 M | 1.45 M | 0 M | — |
| Operating Profit | -28.42 M | -23.14 M | -24.77 M | -16.45 M | -25.36 M | — |
| Net Profit | -25.94 M | -20.17 M | -21.56 M | -12.93 M | -21.13 M | — |
| EPS in Rs | -0.58 | -0.45 | -0.49 | -0.29 | -0.48 | -6.7 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 8.99 M | 0 M | 0 M | 0 M |
| Operating Profit | -92.78 M | -78.19 M | -48.4 M | -39.97 M |
| Net Profit | -80.61 M | -71.11 M | -63.85 M | -39.72 M |
| EPS in Rs | -1.82 | -1.6 | -1.44 | -0.9 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 294.89 M | 358.23 M | 25.92 M | 28.43 M |
| Total Liabilities | 22.84 M | 35.11 M | 199.32 M | 140.99 M |
| Equity | 272.05 M | 323.13 M | -173.4 M | -112.56 M |
| Current Assets | 286.79 M | 357.1 M | 25.31 M | 28.03 M |
| Current Liabilities | 20.14 M | 27.77 M | 58.17 M | 5.86 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -81.63 M | -51.52 M | -37.36 M | -36.18 M |
| Investing CF | -95.22 M | -0.37 M | -0.27 M | -0.1 M |
| Financing CF | 11.47 M | 381.2 M | 34.94 M | 2.5 M |
| Free CF | -82.35 M | -51.89 M | -37.53 M | -36.28 M |
| Capex | -0.72 M | -0.37 M | -0.17 M | -0.1 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -13.35% | -11.36% | -60.75% | — |
| Profit Margin % | -896.11% | — | — | — |
| Operating Margin % | -1031.46% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -885.99% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.